Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial

July 23, 2021

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro(TM) for Early Alzheimer’s Disease

November 27, 2023
Augmedix Announces Closing of Public Offering of Common Stock, Including Additional Investments from HCA Healthcare and Redmile Group

November 21, 2023
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

November 21, 2023
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

November 21, 2023